E Ink and LTS Partner to Develop Smart Patch to Improve Medical Management

E InkE Ink Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and LTS Lohmann-Therapie Systeme AG, "LTS" leading in the development and manufacturing of transdermal therapeutic systems, have announced their partnership to develop a "Smart Patch" prototype. The Smart Patch prototype is a transdermal therapeutic system (TTS) that delivers medication to patients in a convenient, controlled and comfortable manner and features an E Ink display to deliver and convey relevant information about patch performance.

According to a report conducted by the New England Healthcare Institute (NEHI), poor medication adherence is a pervasive problem that costs $290 billion a year in the U.S. Forgetting to take medication and not understanding administration instructions are among the main reasons why between 20 and 50 percent of patients are not adhering to their medical regimens. Smart drug systems like Smart Patches will increase globally to nearly $81.4 billion by 2024 as they provide a more targeted, uniform and secure method of drug delivery.

"Poor medical adherence negatively impacts patients’ therapeutic outcomes, leading to more hospitalizations and higher total costs," said Dr. Hanshermann Franke, Corp. VP of R&D at LTS. "The main purpose of any innovation must be centered on the idea of making patients’ lives as healthy and comfortable as possible. This can be achieved by designing "smart" solutions that easily integrate, facilitate treatment monitoring and help patients use their medication properly."

The Smart Patch is equipped with a 2” E Ink electronic paper display (EPD) that leverages the display’s bistable nature to ensure the patient doesn’t need to recharge the battery. The patch features a switch, pressure sensor and a low voltage E Ink display that shows helpful information with functionalities including:

  • A message indicating whether the patch is applied correctly to the skin
  • A countdown until the next dose
  • A reminder to remove the patch and to replace it appropriately

"This is the first application to feature E Ink’s low voltage film, which uses 50-70 percent of the typical driving voltage for EPDs," said Dr. FY Gan, EVP of Sales Center at E Ink. "In addition to minimizing power consumption, which results in the ability to use a small battery with a longer battery life, the low voltage film is the thinnest electronic paper film available on the market at less than 200um, enabling it to fit flawlessly on the TTS."

"There are many advantages to TTS technologies, and now we can add a decisive enhancement - an E Ink display," said Dr. Tim Schlange, CMO at LTS. "This feature allows LTS to provide functionalities to patients with more reliable, safe and pain-free applications and to further enhance the value of solutions for its partners in the pharmaceutical industry."

"Medical innovation is happening at an unprecedented rate and we are excited to partner with a company that is providing unique drug delivery systems in the marketplace to improve medical compliance," said Dr. Paul Apen, Chief Strategy Officer at E Ink. "Our displays are a natural fit for this type of drug delivery system as they are thin, have a wide viewing angle and consume minimal power for continued use. This is just one of the ways our display technology is impacting the future of medical applications."

The Smart Patch concept will initially target the treatment of chronic diseases. The first prototype will be displayed during CPhI in Messe Frankfurt, Germany October 24-26, 2017 at LTS's booth 4.0 C40.

About E Ink Holdings
E Ink Holdings Inc. (8069.TWO), based on technology from MIT’s Media Lab, has transformed and defined the eReader market and is redefining the signage, architecture and design, mobile, wearable and retail markets with its ePaper technology, enabling a new multi-billion dollar market in less than 10 years. Its corporate philosophy aims to deliver revolutionary products, user experiences and environmental benefits through advanced technology development. This vision has led to its continuous investments in the field of ePaper displays as well as expanding the use of its technologies into a number of other markets and applications including smart packaging and fashion. Its Electrophoretic Display products make it the worldwide leader for ePaper. Its Fringe Field Switching (FFS) technologies are a standard for high-end LCD displays and have been licensed to all major liquid crystal display makers in the world. Listed in Taiwan's Taipei Exchange (TPEx) and the Luxembourg market, E Ink Holdings is now the world's largest supplier of ePaper displays.

About LTS Lohmann Therapie Systeme AG
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS") and Oral Thin Films ("OTF") for the pharmaceutical industry. LTS's innovation model consists of both partner-funded and self-funded initiatives currently encompassing more than 20 marketed products and a deep and diverse pipeline of development projects targeting multiple disease indications. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representation in Shanghai, China.

Most Popular Now

MSD Innovation Factory Selects 3 Compani…

Throughout the MSD Innovation Factory, MSD launched 7 health-related challenges to award the three most outstanding solutions. Blendarsys, Symptoma and Grupo Pulso are the winners out of 100 proposals. The...

Using Virtual Reality to Identify Brain …

Virtual reality is helping neuroscientists at the University of California, Davis, get new insight into how different brain areas assemble memories in context. In a study published Jan. 18 in...

People with Tetraplegia Gain Rapid Use o…

For a brain-computer interface (BCI) to be truly useful for a person with tetraplegia, it should be ready whenever it's needed, with minimal expert intervention, including the very first time...

East Lancashire Hospitals Chooses Cerner…

East Lancashire Hospitals NHS Trust (ELHT) has chosen global health information technology leader Cerner as its Preferred Supplier of a new clinical information system that will help to improve the...

Hamlyn Centre Announces Grant from Bill …

The Hamlyn Centre at Imperial College London today announces the award of a grant from the Bill & Melinda Gates Foundation, to accelerate research into new integrated technology systems for...

Philips Debuts Fully Integrated Suite o…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the launch of its next-generation Patient Monitoring solution in the U.S. The enterprise-wide system consists of bedside...

Liverpool Awards Contract to Docobo

One of the best-known users of telehealth in England has awarded a contract to Docobo to significantly expand its service over the next three years. NHS Liverpool Clinical Commissioning Group...

Augmented Reality System Lets Doctors Se…

New technology is bringing the power of augmented reality into clinical practice. The system, called ProjectDR, allows medical images such as CT scans and MRI data to be displayed directly...

Assessing Health Technology in the EU: C…

European Commission has put forward a proposal to boost cooperation amongst EU Member States for assessing health technology. Greater transparency will empower patients, by ensuring their access to information on...

ProEmpower Releases Call for Tenders to …

The ProEmpower procurers are looking for a diabetes management solution that will tackle the unmet needs in the current treatment of diabetes such as the fragmentation in today’s healthcare systems...

Biosensors Will Be Inexpensive, Do More…

When it comes to biometric sensors, human skin isn't an ally. It's an obstacle. The University of Cincinnati is developing cutting-edge methods to overcome this barrier without compromising the skin...